Targeted adjunctive intracoronary delivery of the low-dose recombinant tissue plasminogen activator alteplase does not improve microvascular obstruction or major adverse cardiovascular events (MACE) in patients undergoing primary PCI for a large territory STEMI and high thrombus burden, according to results from the STRIVE trial presented at TCT 2025 and simultaneously published in JACC.

Compared with drug-eluting stent (DES) implantation, use of drug-coated balloons (DCB) as an alternative for treating de novo coronary artery disease (CAD) was associated with a significantly higher rate of cardiovascular death, target vessel myocardial infarction (TV-MI) and clinically and physiologically indicated target lesion revascularization (TLR) at three years, based on new findings from REC-CAGEFREE 1, presented at TCT 2025 and simultaneously published in JACC.

In patients presenting with graft failure after a CABG, PCI of the saphenous vein grafts (SVG), compared with native vessels, was associated with better one-year clinical outcomes, based on findings from the PROCTOR trial presented at TCT 2025 and simultaneously published in JACC. In presenting the findings, Ruben W. de Winter, MD, noted these results were primarily riven by lower rates of PCI-related myocardial infarction (MI) and clinically driven target coronary territory revascularization.

Transcatheter mitral valve replacement (TMVR) with use of the Tendyne transcatheter mitral valve system was successful in treating mitral valve disease due to mitral annulus calcification (MAC), and significantly improved heart failure (HF) symptoms and quality of life (QOL), according to a first report of the primary outcomes of the SUMMIT-MAC trial presented at TCT 2025 and simultaneously published in JACC.